Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Market Momentum | Analyst targets range from $3 to $11, with potential $1B+ valuation if ECO Synthesis platform succeeds in capturing siRNA manufacturing market share |
Collaborative Horizons | Explore Codexis's strategic partnerships, including plans for a major pharma collaboration and CDMO partnerships showcasing RNA ligases |
Financial Fortitude | $60M cash cushion funds operations through 2026, aiming for positive cash flow, despite recent revenue decline and negative profit margins |
Enzymatic Revolution | Codexis pivots to siRNA therapeutics manufacturing, potentially transforming the industry with its innovative ECO Synthesis platform |
Metrics to compare | CDXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCDXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −3.2x | −0.6x | |
PEG Ratio | −0.16 | 0.00 | 0.00 | |
Price / Book | 3.9x | 1.1x | 2.6x | |
Price / LTM Sales | 2.8x | 4.4x | 3.2x | |
Upside (Analyst Target) | 324.2% | 137.7% | 41.8% | |
Fair Value Upside | Unlock | 7.2% | 5.1% | Unlock |